The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks

被引：7

作者：

Longhurst, Hilary J. ^{[1
]}

Aberer, Werner ^{[2
]}

Bouillet, Laurence ^{[3
]}

Caballero, Teresa ^{[4
]}

Maurer, Marcus ^{[5
]}

Fabien, Vincent ^{[6
]}

Zanichelli, Andrea ^{[7
]}

机构：

[1] Barts Hlth NHS Trust, Dept Immunol, Graz, Austria

[2] Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria

[3] Grenoble Univ Hosp, Natl Reference Ctr Angioedema, Dept Internal Med, Grenoble, France

[4] Hosp La Paz, Inst Hlth Res IdiPaz, Dept Allergy, Biomed Res Network Rare Dis,CIBERER,U754, Madrid, Spain

[5] Charite, Allergie Centrum Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany

[6] Shire, Zug, Switzerland

[7] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci, Milan, Italy

来源：

EUROPEAN JOURNAL OF EMERGENCY MEDICINE | 2016年 / 23卷 / 03期

关键词：

acquired angioedema; C1-inhibitor deficiency; hereditary angioedema; icatibant; laryngeal edema; observational study; therapy; HEREDITARY ANGIOEDEMA; RECEPTOR ANTAGONIST;

D O I：

10.1097/MEJ.0000000000000292

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Objective To characterize the management and outcomes of life-threatening laryngeal attacks of hereditary angioedema (HAE) treated with icatibant in the observational Icatibant Outcome Survey (NCT01034969) registry. Methods This retrospective analysis was based on data from patients with HAE type I/II who received healthcare professional-administered or self-administered icatibant to treat laryngeal attacks between September 2008 and May 2013. Results Twenty centers in seven countries contributed data. Overall, 42 patients with HAE experienced 67 icatibant-treated laryngeal attacks. Icatibant was selfadministered for 62.3% of attacks (healthcare professionaladministered, 37.7%). One icatibant injection was used for 87.9% of attacks, with rescue or concomitant medication used for 9.0%. The median time to treatment was 2.0 h (n=31 attacks) and the median time to resolution was 6.0 h (n=35 attacks). Conclusions This analysis describes successful use of icatibant for the treatment of laryngeal HAE attacks in a real-world setting. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

引用

页码：224 / 227

页数：4

共 10 条

[1] Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema [J].

Bernstein J.A. ;

Moellman J. .

International Journal of Emergency Medicine, 5 (1)

[2] Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema [J].

Bork, K ;

Barnstedt, SE .

ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (05) :714-718

[3] Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency [J].

Bork, Konrad ;

Hardt, Jochen ;

Witzke, Guenther .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 130 (03) :692-697

[4] Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema [J].

Cicardi, M. ;

Banerji, A. ;

Bracho, F. ;

Malbran, A. ;

Rosenkranz, B. ;

Riedl, M. ;

Bork, K. ;

Lumry, W. ;

Aberer, W. ;

Bier, H. ;

Bas, M. ;

Greve, J. ;

Hoffmann, T. K. ;

Farkas, H. ;

Reshef, A. ;

Ritchie, B. ;

Yang, W. ;

Grabbe, J. ;

Kivity, S. ;

Kreuz, W. ;

Levy, R. J. ;

Luger, T. ;

Obtulowicz, K. ;

Schmid-Grendelmeier, P. ;

Bull, C. ;

Sitkauskiene, B. ;

Smith, W. B. ;

Toubi, E. ;

Werner, S. ;

Anne, S. ;

Bjorkander, J. ;

Bouillet, L. ;

Cillari, E. ;

Hurewitz, D. ;

Jacobson, K. W. ;

Katelaris, C. H. ;

Maurer, M. ;

Merk, H. ;

Bernstein, J. A. ;

Feighery, C. ;

Floccard, B. ;

Gleich, G. ;

Hebert, J. ;

Kaatz, M. ;

Keith, P. ;

Kirkpatrick, C. H. ;

Langton, D. ;

Martin, L. ;

Pichler, C. ;

Resnick, D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (06) :532-541

[5]

Craig T, 2012, WORLD ALLERGY ORGAN, V5, P182, DOI 10.1097/WOX.0b013e318279affa

[6]

European Medicines Agency, 2019, FIR SUMM PROD CHAR

[7] Hereditary angioedema: a survey of UK emergency departments and recommendations for management [J].

Jaiganesh, Thiagarajan ;

Hughan, Chris ;

Webster, Anthony ;

Bethune, Claire .

EUROPEAN JOURNAL OF EMERGENCY MEDICINE, 2012, 19 (04) :271-274

[8] HAE international home therapy consensus document [J].

Hilary J Longhurst ;

Henriette Farkas ;

Timothy Craig ;

Emel Aygören-Pürsün ;

Claire Bethune ;

Janne Bjorkander ;

Konrad Bork ;

Laurence Bouillet ;

Henrik Boysen ;

Anette Bygum ;

Teresa Caballero ;

Marco Cicardi ;

John Dempster ;

Mark Gompels ;

Jimmy Gooi ;

Sofia Grigoriadou ;

Ursula Huffer ;

Wolfhart Kreuz ;

Marcel M Levi ;

Janet Long ;

Inmaculada Martinez-Saguer ;

Michel Raguet ;

Avner Reshef ;

Tom Bowen ;

Bruce Zuraw .

Allergy, Asthma & Clinical Immunology, 6 (1)

[9] Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial [J].

Lumry, William R. ;

Li, H. Henry ;

Levy, Robyn J. ;

Potter, Paul C. ;

Farkas, Henriette ;

Moldovan, Dumitru ;

Riedl, Marc ;

Li, Hongbin ;

Craig, Timothy ;

Bloom, Bradley J. ;

Reshef, Avner .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (06) :529-537

[10] Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment [J].

Maurer, Marcus ;

Aberer, Werner ;

Bouillet, Laurence ;

Caballero, Teresa ;

Fabien, Vincent ;

Kanny, Gisele ;

Kaplan, Allen ;

Longhurst, Hilary ;

Zanichelli, Andrea .

PLOS ONE, 2013, 8 (02)

← 1 →